Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy

References

• Alderden RA, Hall MD, Hambley TW. The discovery and development of cisplatin. J Chem Educ. 2006;83(5):728. doi:10.1021/ed083p728
   Web of Science ®Google Scholar
• Muggia FM, Bonetti A, Hoeschele JD, Rozencweig M, Howell SB. Platinum antitumor complexes: 50 Years since Barnett Rosenberg’s discovery. J Clin Oncol. 2015;33(35):4219–4226. doi:10.1200/JCO.2015.60.7481
   PubMed Web of Science ®Google Scholar
• Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode [17]. Nature. 1965;205(4972):698–699. doi:10.1038/205698a0
   PubMed Web of Science ®Google Scholar
• IARC, International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42; SUPPLEMENT 7. IARC Monogr Eval Carcinog RISKS TO HUMANS - Overall Eval Carcinog An Update IARC Monographs; 1987.
   Google Scholar
• The Department of Chemistry at the University of Akron. Akron the chemical database; 2009. Available from: https://pubchem.ncbi.nlm.gov/compound/cis-Platin . Accessed March 04, 2021.
   Google Scholar
• HSDB. Hazardous substances data bank; 2009. Available from: https://www.nlm.nih.gov/toxnet/index.html. Accessed November 24, 2020.
   Google Scholar
• Lippert B. In: Lippert B, editor. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. John Wiley & Sons; 2006. doi:10.1002/9783906390420
   Google Scholar
• Cepeda V, Fuertes M, Castilla J, Alonso C, Quevedo C, Perez J. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2008. doi:10.2174/187152007779314044
   Web of Science ®Google Scholar
• Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002. doi:10.1073/pnas.162491399
   Web of Science ®Google Scholar
• Brown A, Kumar S, Tchounwou PB. Cisplatin-based chemotherapy of human cancers. J Cancer Sci Ther. 2019;11(4).
   Google Scholar
• Fichtinger-Schepman AMJ, Lohman PHM, van der Veer JL, den Hartog JHJ, Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry. 1985;24(3):707–713. doi:10.1021/bi00324a025
   PubMed Web of Science ®Google Scholar
• Beck DJ, Brubaker RR. Effect of cis platinum (II) diamminodichloride on wild type and deoxyribonucleic acid repair deficient mutants of Escherichia coli. J Bacteriol. 1973;116(3):1247–1252. doi:10.1128/jb.116.3.1247-1252.1973
   Web of Science ®Google Scholar
• Fraval HNA, Rawlings CJ, Roberts JJ. Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. Mutat Res Fundam Mol Mech Mutagen. 1978;51(1):121–132. doi:10.1016/0027-5107(78)90014-3
   Web of Science ®Google Scholar
• Kumar S, Tchounwou PB. Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells. Oncotarget. 2015;6(38):40734–40746. doi:10.18632/oncotarget.5754
   Google Scholar
• Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, LLeonart ME. Oxidative stress and cancer: an overview. Ageing Res Rev. 2013;12(1):376–390. doi:10.1016/j.arr.2012.10.004
   PubMed Web of Science ®Google Scholar
• Ueda N, Kaushal GP, Shah SV. Apoptotic mechanisms in acute renal failure. Am J Med. 2000;108(5):403–415. doi:10.1016/S0002-9343(00)00311-9
   Web of Science ®Google Scholar
• Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol. 1996. doi:10.1152/ajprenal.1996.270.4.f700
   Web of Science ®Google Scholar
• Matsushima H, Yonemura K, Ohishi K, Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med. 1998;131(6):518–526. doi:10.1016/S0022-2143(98)90060-9
   PubMed Web of Science ®Google Scholar
• Shaloam RD. Preclinical assessment of low doses of cisplatin in the management of acute promyelocytic leukemia. Int J Cancer Res Mol Mech. 2015. doi:10.16966/2381-3318.113
   Google Scholar
• Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta Pharm Sin B. 2017;7(1):3–17. doi:10.1016/j.apsb.2016.11.001
   PubMed Web of Science ®Google Scholar
• Zhu H, Zhang H, Jin F, et al. Elevated Orai1 expression mediates tumor-promoting intracellular Ca2+ oscillations in human esophageal squamous cell carcinoma. Oncotarget. 2014;5(11):3455–3471. doi:10.18632/oncotarget.1903
   PubMedGoogle Scholar
• Shen L, Wen N, Xia M, et al. Calcium efflux from the endoplasmic reticulum regulates cisplatin-induced apoptosis in human cervical cancer HeLa cells. Oncol Lett. 2016;11(4):2411–2419. doi:10.3892/ol.2016.4278
   Web of Science ®Google Scholar
• Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem. 2003. doi:10.1074/jbc.M210284200
   Web of Science ®Google Scholar
• Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020. doi:10.1038/s41571-020-0341-y
   Web of Science ®Google Scholar
• Fernald K, Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol. 2013;23(12):620–633. doi:10.1016/j.tcb.2013.07.006
   PubMed Web of Science ®Google Scholar
• Perfettini JL, Castedo M, Nardacci R, et al. Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope. J Exp Med. 2005;201(2):279–289. doi:10.1084/jem.20041502
   PubMed Web of Science ®Google Scholar
• Benhar M, Dalyot I, Engelberg D, Levitzki A. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol. 2001;21(20):6913–6926. doi:10.1128/mcb.21.20.6913-6926.2001
   PubMed Web of Science ®Google Scholar
• Jeong HG, Cho HJ, Chang IY, et al. Rac1 prevents cisplatin-induced apoptosis through down-regulation of p38 activation in NIH3T3 cells. FEBS Lett. 2002. doi:10.1016/S0014-5793(02)02674-1
   Web of Science ®Google Scholar
• Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol. 2001. doi:10.1124/mol.59.4.657
   Web of Science ®Google Scholar
• Ashrafizadeh M, Ahmadi Z, Farkhondeh T, Samarghandian S. Autophagy as a molecular target of quercetin underlying its protective effects in human diseases. Arch Physiol Biochem. 2019. doi:10.1080/13813455.2019.1671458
   Web of Science ®Google Scholar
• Basu A. The potential of protein kinase C as A target for anticancer treatment. Pharmacol Ther. 1993;59(3):257–280. doi:10.1016/0163-7258(93)90070-T
   Web of Science ®Google Scholar
• Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992;258(5082):607–614. doi:10.1126/science.1411571
   PubMed Web of Science ®Google Scholar
• Erhardt P, Schremser EJ, Cooper GM. B-RAF inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol. 1999. doi:10.1128/mcb.19.8.5308
   Web of Science ®Google Scholar
• Tashker JS, Olson M, Kornbluth S. Post-cytochrome c protection from apoptosis conferred by a MAPK pathway in Xenopus egg extracts. Mol Biol Cell. 2002. doi:10.1091/mbc.01-06-0291
   Web of Science ®Google Scholar
• Nowak G. Protein kinase C-α and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem. 2002. doi:10.1074/jbc.M206373200
   Web of Science ®Google Scholar
• Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911–1912. doi:10.1126/science.1072682
   PubMed Web of Science ®Google Scholar
• Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37–40. doi:10.1038/35065000
   PubMed Web of Science ®Google Scholar
• Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80(2):179–185. doi:10.1016/0092-8674(95)90401-8
   PubMed Web of Science ®Google Scholar
• Ueda Y, Hirai SI, Osada SI, Suzuki A, Mizuno K, Ohno S. Protein kinase C δ activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem. 1996. doi:10.1074/jbc.271.38.23512
   Web of Science ®Google Scholar
• Basu A, Tu H. Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cδ. Biochem Biophys Res Commun. 2005. doi:10.1016/j.bbrc.2005.06.199
   Web of Science ®Google Scholar
• Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103(2):239–252. doi:10.1016/S0092-8674(00)00116-1
   PubMed Web of Science ®Google Scholar
• Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Genet Dev. 2002;12(1):14–21. doi:10.1016/S0959-437X(01)00258-1
   PubMed Web of Science ®Google Scholar
• Potapova O, Haghighi A, Bost F, et al. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem. 1997;272(22):14041–14044. doi:10.1074/jbc.272.22.14041
   Web of Science ®Google Scholar
• Hayakawa J, Ohmichi M, Kurachi H, et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N- terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem. 1999;274(44):31648–31654. doi:10.1074/jbc.274.44.31648
   Web of Science ®Google Scholar
• Potapova O, Basu S, Mercola D, Holbrook NJ. Protective role for c-Jun in the cellular response to DNA damage. J Biol Chem. 2001. doi:10.1074/jbc.M102075200
   Web of Science ®Google Scholar
• Yan D, An GY, Kuo MT. c-jun N-terminal kinase signalling pathway in response to cisplatin. J Cell Mol Med. 2016. doi:10.1111/jcmm.12908
   Web of Science ®Google Scholar
• Gupta J, Nebreda AR. Roles of p38α mitogen-activated protein kinase in mouse models of inflammatory diseases and cancer. FEBS J. 2015. doi:10.1111/febs.13250
   Web of Science ®Google Scholar
• Grossi V, Peserico A, Tezil T, Simone C. p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. World J Gastroenterol. 2014;20(29):9744. doi:10.3748/wjg.v20.i29.9744
   PubMed Web of Science ®Google Scholar
• Pereira L, Igea A, Canovas B, Dolado I, Nebreda AR. Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med. 2013;5(11):1759–1774. doi:10.1002/emmm.201302732
   Web of Science ®Google Scholar
• Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64(7):2343–2346. doi:10.1158/0008-5472.CAN-03-3856
   PubMed Web of Science ®Google Scholar
• Burgering BMT, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995;376(6541):599–602. doi:10.1038/376599a0
   PubMed Web of Science ®Google Scholar
• Wick MJ, Dong LQ, Riojas RA, Ramos FJ, Liu F. Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositide-dependent protein kinase-1. J Biol Chem. 2000;275(51):40400–40406. doi:10.1074/jbc.M003937200
   PubMed Web of Science ®Google Scholar
• Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46(6):372–383. doi:10.3109/07853890.2014.912836
   PubMed Web of Science ®Google Scholar
• Peng DJ, Wang J, Zhou JY, Wu GS. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun. 2010;394(3):600–605. doi:10.1016/j.bbrc.2010.03.029
   Web of Science ®Google Scholar
• Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer. 2005;117(5):755–763. doi:10.1002/ijc.21242
   Web of Science ®Google Scholar
• Sedletska Y, Giraud-Panis MJ, Malinge JM. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents. 2005;5(3):251–265. doi:10.2174/1568011053765967
   PubMedGoogle Scholar
• Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev. 1999;99(9):2467–2498. doi:10.1021/cr980421n
   PubMed Web of Science ®Google Scholar
• Basu A, Krishnamurthy S. Cellular responses to cisplatin-induced DNA damage. J Nucleic Acids. 2010;2010:1–16. doi:10.4061/2010/201367
   Google Scholar
• Welsh C, Day R, McGurk C, Masters JRW, Wood RD, Köberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer. 2004;110(3):352–361. doi:10.1002/ijc.20134
   PubMed Web of Science ®Google Scholar
• Köberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JRW. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer. 1997;70(5):551–555. doi:10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G
   Web of Science ®Google Scholar
• Avdievich E, Reiss C, Scherer SJ, et al. Distinct effects of the recurrent Mlh1G67R mutation on MMR functions, cancer, and meiosis. Proc Natl Acad Sci U S A. 2008;105(11):4247–4252. doi:10.1073/pnas.0800276105
   Web of Science ®Google Scholar
• Yang G, Scherer SJ, Shell SS, et al. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell. 2004;6(2):139–150. doi:10.1016/j.ccr.2004.06.024
   Web of Science ®Google Scholar
• Lin DP, Wang Y, Scherer SJ, et al. An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res. 2004;64(2):517–522. doi:10.1158/0008-5472.CAN-03-2957
   Web of Science ®Google Scholar
• Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 2003;10(4):431–442. doi:10.1038/sj.cdd.4401183
   PubMed Web of Science ®Google Scholar
• De Laurenzi V, Melino G. Evolution of functions within the p53/p63/p73 family. Ann N Y Acad Sci. 2000;926:90–100. doi:10.1111/j.1749-6632.2000.tb05602.x
   PubMed Web of Science ®Google Scholar
• Abedini MR, Muller EJ, Brun J, Bergeron R, Gray DA, Tsang BK. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res. 2008. doi:10.1158/0008-5472.CAN-08-0673
   Web of Science ®Google Scholar
• Sirvent A, Benistant C, Roche S. Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell. 2008. doi:10.1042/bc20080020
   Web of Science ®Google Scholar
• Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer Therapy. Cancer. 1994;73(8):2013–2026. doi:10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J
   PubMed Web of Science ®Google Scholar
• Persons DL, Yazlovitskaya EM, Pelling JC. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem. 2000;275(46):35778–35785. doi:10.1074/jbc.M004267200
   PubMed Web of Science ®Google Scholar
• Brown R, Clugston C, Edlin A, et al. Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell lines. Int J Cancer. 1993;55(4):678–684. doi:10.1002/ijc.2910550428
   Web of Science ®Google Scholar
• Kharbanda S, Ren R, Pandey P, et al. Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents. Nature. 1995;376(6543):785–788. doi:10.1038/376785a0
   PubMed Web of Science ®Google Scholar
• Tsai KKC, Yuan ZM. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res. 2003.
   Web of Science ®Google Scholar
• Galan-Moya EM, Hernandez-Losa J, Aceves Luquero CI, et al. C-Abl activates p38 MAPK independently of its tyrosine kinase activity: implications in cisplatin-based therapy. Int J Cancer. 2008. doi:10.1002/ijc.23063
   Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883. doi:10.1038/onc.2011.384
   PubMed Web of Science ®Google Scholar
• Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet. 2007;81(3):427–437. doi:10.1086/519850
   Web of Science ®Google Scholar
• Sakamoto M, Kondo A, Kawasaki K, et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell. 2001.
   Google Scholar
• Covert MW, Knight EM, Reed JL, Herrgard MJ, Palsson BO. Integrating high-throughput and computational data elucidates bacterial networks. Nature. 2004;429(6987):92–96. doi:10.1038/nature02456
   PubMed Web of Science ®Google Scholar
• Nabil M, Zunino P. A computational study of cancer hyperthermia based on vascular magnetic nanoconstructs. R Soc Open Sci. 2016;3(9):160287. doi:10.1098/rsos.160287
   PubMed Web of Science ®Google Scholar
• Aprile F, Martin DS. Chlorotriammineplatinum(II) Ion. Acid hydrolysis and isotopic exchange of chloride ligand. Inorg Chem. 1962;1(3):551–557. doi:10.1021/ic50003a021
   Web of Science ®Google Scholar
• Burda JV, Zeizinger M, Leszczynski J. Hydration process as an activation of trans- and cisplatin complexes in anticancer treatment. DFT and Ab initio computational study of thermodynamic and kinetic parameters. J Comput Chem. 2005;26(9):907–914. doi:10.1002/jcc.20228
   Web of Science ®Google Scholar
• Henderson RA. Kinetics and mechanism of reactions of transition metal complexes. J Organomet Chem. 1992. doi:10.1016/0022-328x(92)83075-s
   Google Scholar
• Platts JA, Hibbs DE, Hambley TW, Hall MD. Calculation of the hydrophobicity of platinum drugs. J Med Chem. 2001. doi:10.1021/jm001080k
   Web of Science ®Google Scholar
• Baik MH, Friesner RA, Lippard SJ. Theoretical study of cisplatin binding to purine bases: why does cisplatin prefer guanine over adenine? J Am Chem Soc. 2003;125(46):14082–14092. doi:10.1021/ja036960d
   Web of Science ®Google Scholar
• Zimmermann T, Burda JV. Reactions of cisplatin with cysteine and methionine at constant pH; A computational study. Dalton Trans. 2010. doi:10.1039/b913803j
   Web of Science ®Google Scholar
• Tasinato N, Puzzarini C, Barone V. Correct modeling of cisplatin: a paradigmatic case. Angew Chem Int Ed. 2017. doi:10.1002/anie.201707683
   Web of Science ®Google Scholar
• Chen HHW, Song IS, Hossain A, et al. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Mol Pharmacol. 2008;74(3):697–704. doi:10.1124/mol.108.047969
   PubMed Web of Science ®Google Scholar
• Bano N, Najam R, Qazi F. Adverse cardiac manifestations of cisplatin - A review. Int J Pharm Sci Rev Res. 2013.
   Google Scholar
• Jefford M, Michael M, Rosenthal MA, et al. A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer. Invest New Drugs. 2004;22(2):185–192. doi:10.1023/B:DRUG.0000011796.20332.a9
   Web of Science ®Google Scholar
• Price PM, Safirstein RL, Megyesi J. Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am J Physiol Ren Physiol. 2004. doi:10.1152/ajprenal.00192.2003
   Web of Science ®Google Scholar
• Berry JM, Jacobs C, Sikic B, Halsey J, Borch RF. Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol. 1990;8(9):1585–1590. doi:10.1200/JCO.1990.8.9.1585
   Web of Science ®Google Scholar
• Kuhlmann MK, Burkhardt G, Köhler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant. 1997. doi:10.1093/ndt/12.12.2478
   Web of Science ®Google Scholar
• Bhattacharyya S, Mehta P. The hepatoprotective potential of Spirulina and vitamin C supplemention in cisplatin toxicity. Food Funct. 2012;3(2):164–169. doi:10.1039/c1fo10172b
   PubMed Web of Science ®Google Scholar
• Amin A, Hamza AEA. Effects of Roselle and Ginger on cisplatin-induced reproductive toxicity in rats. Asian J Androl. 2006. doi:10.1111/j.1745-7262.2006.00179.x
   Web of Science ®Google Scholar
• Ibrahim A, Eldaim MAA, Abdel-Daim MM. Nephroprotective effect of bee honey and royal jelly against subchronic cisplatin toxicity in rats. Cytotechnology. 2016;68(4):1039–1048. doi:10.1007/s10616-015-9860-2
   PubMed Web of Science ®Google Scholar
• Cersosimo RJ. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharmacother. 1993;27(4):438–441. doi:10.1177/106002809302700408
   Web of Science ®Google Scholar
• Liu J, Liu Y, Habeebu SSM, Klaassen CD. Metallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity. Toxicol Appl Pharmacol. 1998. doi:10.1006/taap.1997.8325
   Web of Science ®Google Scholar
• Lu Y, Cederbaum AI. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol Sci. 2006;89(2):515–523. doi:10.1093/toxsci/kfj031
   PubMed Web of Science ®Google Scholar
• Pezeshki Z, Khosravi A, Nekuei M, et al. Time course of cisplatin-induced nephrotoxicity and hepatotoxicity. J Nephropathol. 2017;6(3):163–167. doi:10.15171/jnp.2017.28
   PubMedGoogle Scholar
• El-Awady ESE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies. Eur J Pharmacol. 2011;650(1):335–341. doi:10.1016/j.ejphar.2010.09.085
   PubMed Web of Science ®Google Scholar
• Dieckmann KP, Struss WJ, Budde U. Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer Res. 2011;31(12):4501–4505.
   PubMed Web of Science ®Google Scholar
• Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anticancer Drugs. 2008;19(9):927–929. doi:10.1097/CAD.0b013e3283100e9c
   Web of Science ®Google Scholar
• Patanè S. Cardiotoxicity: cisplatin and long-term cancer survivors. Int J Cardiol. 2014. doi:10.1016/j.ijcard.2014.04.238
   Web of Science ®Google Scholar
• Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115–124. doi:10.1097/MAJ.0b013e31812dfe1e
   PubMed Web of Science ®Google Scholar
• Tanaka H, Ishikawa E, Teshima S, Shimizu E. Histopathological study of human cisplatin nephropathy. Toxicol Pathol. 1986;14(2):247–257. doi:10.1177/019262338601400215
   PubMedGoogle Scholar
• Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993;50(2):147–158. doi:10.1006/gyno.1993.1184
   PubMed Web of Science ®Google Scholar
• Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Ren Physiol. 2009;296(3):F505–F511. doi:10.1152/ajprenal.90545.2008
   PubMed Web of Science ®Google Scholar
• Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel). 2010;2(11):2490–2518. doi:10.3390/toxins2112490
   PubMed Web of Science ®Google Scholar
• Hwa Lee R, Mi Song J, Young Park M, Kyung Kang S, Keun Kim Y, Sup Jung J. Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem Pharmacol. 2001. doi:10.1016/S0006-2952(01)00748-1
   Web of Science ®Google Scholar
• Aldossary SA. Review on pharmacology of cisplatin: clinical use, toxicity and mechanism of resistance of cisplatin. Biomed Pharmacol J. 2019;12(1):07–15. doi:10.13005/bpj/1608
   Google Scholar
• Cavaletti G, Pezzoni G, Pisano C, et al. Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neurosci Lett. 2002;322(2):103–106. doi:10.1016/S0304-3940(02)00091-5
   PubMed Web of Science ®Google Scholar
• Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 2007;226(1–2):157–167. doi:10.1016/j.heares.2006.09.015
   PubMed Web of Science ®Google Scholar
• Waissbluth S, Daniel SJ. Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity. Hear Res. 2013;299:37–45. doi:10.1016/j.heares.2013.02.002
   PubMed Web of Science ®Google Scholar
• Colpi GM, Contalbi GF, Nerva F, Sagone P, Piediferro G. Testicular function following chemo-radiotherapy. Eur J Obstet Gynecol Reprod Biol. 2004;113:S2–S6. doi:10.1016/j.ejogrb.2003.11.002
   PubMed Web of Science ®Google Scholar
• Malarvizhi D, Mathur PP. Effects of cisplatin on testicular functions in rats. Indian J Exp Biol. 1996.
   Google Scholar
• Cherry SM, Hunt PA, Hassold TJ. Cisplatin disrupts mammalian spermatogenesis, but does not affect recombination or chromosome segregation. Mutat Res Genet Toxicol Environ Mutagen. 2004;564(2):115–128. doi:10.1016/j.mrgentox.2004.08.010
   PubMed Web of Science ®Google Scholar
• Wilding G, Caruso R, Lawrence TS, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol. 1985;3(12):1683–1689. doi:10.1200/JCO.1985.3.12.1683
   PubMed Web of Science ®Google Scholar
• Miller DF, Bay JW, Lederman RJ, Purvis JD, Rogers LR, Tomsak RL. Ocular and orbital toxicity following intracarotid injection of BCNU (Carmustine) and cisplatinum for malignant gliomas. Ophthalmology. 1985;92(3):402–406. doi:10.1016/S0161-6420(85)34036-8
   Web of Science ®Google Scholar
• Zisowsky J, Koegel S, Leyers S, et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol. 2007;73(2):298–307. doi:10.1016/j.bcp.2006.10.003
   PubMed Web of Science ®Google Scholar
• Lee J, Prohaska JR, Thiele DJ. Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. Proc Natl Acad Sci U S A. 2001;98(12):6842–6847. doi:10.1073/pnas.111058698
   PubMed Web of Science ®Google Scholar
• Kuo MT, Chen HHW, Song IS, Savaraj N, Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev. 2007;26(1):71–83. doi:10.1007/s10555-007-9045-3
   PubMed Web of Science ®Google Scholar
• Hromas RA, North JA, Burns CP. Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett. 1987. doi:10.1016/0304-3835(87)90091-7
   Web of Science ®Google Scholar
• Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol. 2003;64(2):466–473. doi:10.1124/mol.64.2.466
   Web of Science ®Google Scholar
• Samimi G, Safaei R, Katano K, et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res. 2004;10(14):4661–4669. doi:10.1158/1078-0432.CCR-04-0137
   PubMed Web of Science ®Google Scholar
• Safaei R, Otani S, Larson BJ, Rasmussen ML, Howell SB. Transport of cisplatin by the copper efflux transporter ATP7B. Mol Pharmacol. 2008;73(2):461–468. doi:10.1124/mol.107.040980
   Web of Science ®Google Scholar
• Xu D, Xi Z, Zhao L, Liu Y. Transporting platinum drugs from a copper chaperone to ATPase: the mechanistic implication of drug efflux mediated cisplatin resistance. Inorg Chem Front. 2014. doi:10.1039/c3qi00068k
   Web of Science ®Google Scholar
• Koike K, Kawabe T, Tanaka T, et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 1997;57(24):5475–5479.
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SPC. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204(3):216–237. doi:10.1016/j.taap.2004.10.012
   PubMed Web of Science ®Google Scholar
• Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A. 1987;84(1):265–269. doi:10.1073/pnas.84.1.265
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58. doi:10.1038/nrc706
   PubMed Web of Science ®Google Scholar
• He C, Sun Z, Hoffman RM, et al. P-glycoprotein overexpression is associated with cisplatin resistance in human osteosarcoma. Anticancer Res. 2019;39(4):1711–1718. doi:10.21873/anticanres.13277
   PubMed Web of Science ®Google Scholar
• Gibalová L, Šereš M, Rusnák A, et al. P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation. Toxicol Vitro. 2012;26(3):435–444. doi:10.1016/j.tiv.2012.01.014
   PubMed Web of Science ®Google Scholar
• Yang L, Li N, Wang H, Jia X, Wang X, Luo J. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep. 2012;28(2):592–600. doi:10.3892/or.2012.1823
   PubMed Web of Science ®Google Scholar
• Kong W, Ling X, Chen Y, et al. Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway. Int J Mol Med. 2020. doi:10.3892/ijmm.2020.4485
   Web of Science ®Google Scholar
• Cheng Q, Liao M, Hu H, Li H, Wu L. Asiatic Acid (AA) sensitizes multidrug-resistant human lung adenocarcinoma A549/DDP cells to cisplatin (DDP) via downregulation of P-Glycoprotein (MDR1) and its targets. Cell Physiol Biochem. 2018;47(1):279–292. doi:10.1159/000489806
   PubMedGoogle Scholar
• Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem. 1993;268(27):20116–20125. doi:10.1016/S0021-9258(20)80702-9
   PubMed Web of Science ®Google Scholar
• Hagrman D, Goodisman J, Dabrowiak JC, Souid AK. Kinetic study on the reaction of cisplatin with metallothionein. Drug Metab Dispos. 2003;31(7):916–923. doi:10.1124/dmd.31.7.916
   Web of Science ®Google Scholar
• Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem. 1994;269(2):787–790. doi:10.1016/S0021-9258(17)42175-2
   PubMed Web of Science ®Google Scholar
• Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1988;241(4874):1813–1815. doi:10.1126/science.3175622
   Web of Science ®Google Scholar
• Siegsmund MJ, Marx C, Seemann O, et al. Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins. Urol Res. 1999;27(3):157–163. doi:10.1007/s002400050103
   Google Scholar
• Komiya K, Matsuda T, Nishio K, Ohmori T, Sugimoto Y, Saijo N. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res. 1991;51(12):3237–3242. doi:10.1016/0169-5002(92)90185-m
   Web of Science ®Google Scholar
• Wülfing C, van Ahlen H, Eltze E, Piechota H, Hertle L, Schmid KW. Metallothionein in bladder cancer: correlation of overexpression with poor outcome after chemotherapy. World J Urol. 2007;25(2):199–205. doi:10.1007/s00345-006-0141-8
   Web of Science ®Google Scholar
• Lee JH, Chae JW, Kim JK, Kim HJ, Chung JY, Kim YH. Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex. J Control Release. 2015;215:82–90. doi:10.1016/j.jconrel.2015.07.015
   Web of Science ®Google Scholar
• Kondo Y, Kuo SM, Watkins SC, Lazo JS. Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res. 1995.
   Web of Science ®Google Scholar
• De Luca A, Parker LJ, Ang WH, et al. A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1. Proc Natl Acad Sci U S A. 2019;116(28):13943–13951. doi:10.1073/pnas.1903297116
   Web of Science ®Google Scholar
• Nebert DW, Vasiliou V. Analysis of the glutathione S-transferase (GST) gene family. Hum Genomics. 2004;1(6):460. doi:10.1186/1479-7364-1-6-460
   PubMedGoogle Scholar
• Ahmad A, Robinson AR, Duensing A, et al. ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol. 2008;28(16):5082–5092. doi:10.1128/mcb.00293-08
   PubMed Web of Science ®Google Scholar
• Bramson J, Panasci LC. Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents. Cancer Res. 1993.
   Web of Science ®Google Scholar
• Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 1999;18(14):2335–2341. doi:10.1038/sj.onc.1202540
   PubMed Web of Science ®Google Scholar
• Brown R, Hirst GL, Gallagher WM, et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 1997;15(1):45–52. doi:10.1038/sj.onc.1201167
   PubMed Web of Science ®Google Scholar
• Shachar S, Ziv O, Avkin S, et al. Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals. EMBO J. 2009;28(4):383–393. doi:10.1038/emboj.2008.281
   PubMed Web of Science ®Google Scholar
• Bassett E, Vaisman A, Tropea KA, et al. Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases β and η. DNA Repair (Amst). 2002;1(12):1003–1016. doi:10.1016/S1568-7864(02)00150-7
   Web of Science ®Google Scholar
• Wang W, Sheng W, Yu C, et al. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells. Oncol Rep. 2015;34(3):1460–1468. doi:10.3892/or.2015.4121
   PubMed Web of Science ®Google Scholar
• Jiang HG, Chen P, Su JY, et al. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells. J Cell Physiol. 2017;232(12):3433–3443. doi:10.1002/jcp.25792
   Web of Science ®Google Scholar
• Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171–182. doi:10.1016/S0092-8674(02)00615-3
   PubMed Web of Science ®Google Scholar
• Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105(44):17079–17084. doi:10.1073/pnas.0806092105
   PubMed Web of Science ®Google Scholar
• Tajeddine N, Galluzzi L, Kepp O, et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene. 2008;27(30):4221–4232. doi:10.1038/onc.2008.63
   PubMed Web of Science ®Google Scholar
• Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Quo Z, Cullen KJ. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res. 2006;12(19):5817–5825. doi:10.1158/1078-0432.CCR-06-1037
   PubMed Web of Science ®Google Scholar
• Choi YM, Kim HK, Shim W, et al. Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation. PLoS One. 2015. doi:10.1371/journal.pone.0135083
   Web of Science ®Google Scholar
• Ahmed EM, Bandopadhyay G, Coyle B, Grabowska A. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Cell Oncol. 2018;41(3):319–328. doi:10.1007/s13402-018-0374-8
   Web of Science ®Google Scholar
• Dong L, Qi N, Ge RM, Cao CL, Lan F, Shen L. Overexpression of CD133 promotes the phosphorylation of Erk in U87MG human glioblastoma cells. Neurosci Lett. 2010;484(3):210–214. doi:10.1016/j.neulet.2010.08.057
   Web of Science ®Google Scholar
• Ahmadi Z, Ashrafizadeh M. Melatonin as a potential modulator of Nrf2. Fundam Clin Pharmacol. 2020;34(1):11–19. doi:10.1111/fcp.12498
   PubMed Web of Science ®Google Scholar
• Farkhondeh T, Folgado SL, Pourbagher-Shahri AM, Ashrafizadeh M, Samarghandian S. The therapeutic effect of resveratrol: focusing on the Nrf2 signaling pathway. Biomed Pharmacother. 2020;127:110234. doi:10.1016/j.biopha.2020.110234
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Fekri HS, Ahmadi Z, Farkhondeh T, Samarghandian S. Therapeutic and biological activities of berberine: the involvement of Nrf2 signaling pathway. J Cell Biochem. 2020;121(2):1575–1585. doi:10.1002/jcb.29392
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Ahmadi Z, Farkhondeh T, Samarghandian S. Back to nucleus: combating with a toxicity using Nrf2 signaling pathway as a promising therapeutic target. Biol Trace Elem Res. 2020;197(1):52–62. doi:10.1007/s12011-019-01980-4
   PubMed Web of Science ®Google Scholar
• Tonelli C, Chio IIC, Tuveson DA. Transcriptional Regulation by Nrf2. Antioxid Redox Signal. 2018;29(17):1727–1745. doi:10.1089/ars.2017.7342
   PubMed Web of Science ®Google Scholar
• Kansanen E, Kuosmanen SM, Leinonen H, Levonenn AL. The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 2013;1(1):45–49. doi:10.1016/j.redox.2012.10.001
   PubMed Web of Science ®Google Scholar
• Dong J, Sulik KK, Chen SY. Nrf2-mediated transcriptional induction of antioxidant response in mouse embryos exposed to ethanol in vivo: implications for the prevention of fetal alcohol spectrum disorders. Antioxid Redox Signal. 2008;10(12):2023–2033. doi:10.1089/ars.2007.2019
   PubMed Web of Science ®Google Scholar
• Cho JM, Manandhar S, Lee HR, Park HM, Kwak MK. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett. 2008;260(1–2):96–108. doi:10.1016/j.canlet.2007.10.022
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: role of microRNAs and upstream mediators. Cell Signal. 2021. doi:10.1016/j.cellsig.2020.109871
   Web of Science ®Google Scholar
• Ashrafizadeh M, Ahmadi Z, Samarghandian S, et al. MicroRNA-mediated regulation of Nrf2 signaling pathway: implications in disease therapy and protection against oxidative stress. Life Sci. 2020;244:117329. doi:10.1016/j.lfs.2020.117329
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. Association of the epithelial–mesenchymal transition (EMT) with cisplatin resistance. Int J Mol Sci. 2020;21(11):4002. doi:10.3390/ijms21114002
   Web of Science ®Google Scholar
• Kryczek I, Lin Y, Nagarsheth N, et al. IL-22+CD4+ T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity. 2014;40(5):772–784. doi:10.1016/j.immuni.2014.03.010
   PubMed Web of Science ®Google Scholar
• Liu W, Wang W, Wang X, Xu C, Zhang N, Di W. Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis. Cancer Lett. 2020. doi:10.1016/j.canlet.2019.12.024
   Web of Science ®Google Scholar
• Chen KJ, Lin SZ, Zhou L, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One. 2011;6(9). doi:10.1371/journal.pone.0024671
   Web of Science ®Google Scholar
• Walch-Rückheim B, Mavrova R, Henning M, et al. Stromal fibroblasts induce CCL20 through IL6/C/EBPβ to support the recruitment of Th17 cells during cervical cancer progression. Cancer Res. 2015;75(24):5248–5259. doi:10.1158/0008-5472.CAN-15-0732
   Web of Science ®Google Scholar
• Ranasinghe R, Eri R. Modulation of the CCR6-CCl20 axis: a potential therapeutic target in inflammation and cancer. Med. 2018. doi:10.3390/medicina54050088
   Web of Science ®Google Scholar
• Sirichanchuen B, Pengsuparp T, Chanvorachote P. Long-term Cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells. Mol Cell Biochem. 2012;364(1–2):11–18. doi:10.1007/s11010-011-1199-1
   Web of Science ®Google Scholar
• Wu HM, Jiang ZF, Ding PS, Shao LJ, Liu RY. Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells. Sci Rep. 2015. doi:10.1038/srep12291
   Web of Science ®Google Scholar
• Zhang X, Qi Z, Yin H, Yang G. Interaction between p53 and ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy. Theranostics. 2019. doi:10.7150/thno.29673
   Web of Science ®Google Scholar
• Zhang N, Yang GQ, Shao XM, Wei L. GAS5 modulated autophagy is a mechanism modulating cisplatin sensitivity in NSCLC cells. Eur Rev Med Pharmacol Sci. 2016.
   Web of Science ®Google Scholar
• Liu Q, Zhu D, Hao B, Zhang Z, Tian Y. Luteolin promotes the sensitivity of cisplatin in ovarian cancer by decreasing PRPA1-medicated autophagy. Cell Mol Biol. 2018;64(6):17. doi:10.14715/cmb/2018.64.6.4
   Web of Science ®Google Scholar
• Takahashi A, Kimura T, Takabatake Y, et al. Autophagy guards against cisplatin-induced acute kidney injury. Am J Pathol. 2012;180(2):517–525. doi:10.1016/j.ajpath.2011.11.001
   PubMed Web of Science ®Google Scholar
• Periyasamy-Thandavan S, Jiang M, Wei Q, Smith R, Yin XM, Dong Z. Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int. 2008;74(5):631–640. doi:10.1038/ki.2008.214
   PubMed Web of Science ®Google Scholar
• Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235(1–2):179–192. doi:10.1016/S0378-5173(01)00986-3
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43. doi:10.1056/nejmoa052985
   PubMed Web of Science ®Google Scholar
• Gibson MK, Li Y, Murphy B, et al. Randomized Phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an Intergroup Trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562–3567. doi:10.1200/JCO.2005.01.057
   PubMed Web of Science ®Google Scholar
• Ilson DH, Forastiere A, Arquette M, et al. A Phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J. 2000;6(5):316–323.
   PubMed Web of Science ®Google Scholar
• Stordal B, Davey R, Systematic A. Review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr Cancer Drug Targets. 2009;9(3):354–365. doi:10.2174/156800909788166592
   Web of Science ®Google Scholar
• Taguchi T. Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU. Oncol. 1997;54(1):12–18. doi:10.1159/000227740
   Google Scholar
• Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol. 2005;23(22):4999–5006. doi:10.1200/JCO.2005.09.017
   PubMed Web of Science ®Google Scholar
• Jeen YT, Yoon SY, Shin SW, et al. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer. 2001;91(12):2288–2293. doi:10.1002/1097-0142(20010615)91:12<2288::AID-CNCR1260>3.0.CO;2-8
   Web of Science ®Google Scholar
• Kubota H, Fukuta K, Yamada K, et al. Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer. J Rural Med. 2017;12(2):112–119. doi:10.2185/jrm.2938
   Google Scholar
• Tsuchiya A, Imai M, Kamimura H, et al. Successful treatment of multiple lung metastases of hepatocellular carcinoma by combined chemotherapy with docetaxel, cisplatin and tegafur/uracil. World J Gastroenterol. 2009;15(14):1779. doi:10.3748/wjg.15.1779
   Web of Science ®Google Scholar
• Suga S, Iwase H, Shimada M, et al. Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin. Intern Med. 1996;35(12):930–936. doi:10.2169/internalmedicine.35.930
   Web of Science ®Google Scholar
• Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan clinical oncology group study (JCOG9205). J Clin Oncol. 2003;21(1):54–59. doi:10.1200/JCO.2003.04.130
   PubMed Web of Science ®Google Scholar
• Carvalho C, Santos R, Cardoso S, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267–3285. doi:10.2174/092986709788803312
   PubMed Web of Science ®Google Scholar
• Tyagi AK, Agarwal C, Chan DCF, Agarwal R. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep. 2004. doi:10.3892/or.11.2.493
   Web of Science ®Google Scholar
• Park SH, Lee Y, Han SH, et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer. 2006;6(1). doi:10.1186/1471-2407-6-3
   Web of Science ®Google Scholar
• Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2006;24(1):36–44. doi:10.1200/JCO.2004.00.7617
   PubMed Web of Science ®Google Scholar
• Pappo A. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. Chin J Clin Oncol. 2010. doi:10.1056/nejmoa0810613
   Google Scholar
• Noble S, Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997. doi:10.2165/00003495-199754030-00009
   Web of Science ®Google Scholar
• Aapro MS, Martin C, Hatty S. Gemcitabine - A safety review. Anticancer Drugs. 1998;9(3):191–202. doi:10.1097/00001813-199803000-00001
   Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. doi:10.1056/nejmoa0908721
   PubMed Web of Science ®Google Scholar
• Peters GJ, Bergman AM, Ruiz Van Haperen VWT, Veerman G, Kuiper CM, Braakhuis BJM. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol. 1995.
   Web of Science ®Google Scholar
• Ma Y, Trump DL, Johnson CS. Vitamin D in combination cancer treatment. J Cancer. 2010;101–107. doi:10.7150/jca.1.101
   Google Scholar
• Sutton ALM, MacDonald PN. Vitamin D: more than a “bone-a-fide” hormone. Mol Endocrinol. 2003;17(5):777–791. doi:10.1210/me.2002-0363
   Google Scholar
• Brown AJ, Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspects Med. 2008;29(6):433–452. doi:10.1016/j.mam.2008.04.001
   PubMed Web of Science ®Google Scholar
• Cho YL, Deppe G, Malviya VK, Malone JM, Saunders DE. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res. 1991;51(11):2848–2853.
   Web of Science ®Google Scholar
• Huang Z, Zhang Y, Li H, et al. Vitamin D promotes the cisplatin sensitivity of oral squamous cell carcinoma by inhibiting LCN2-modulated NF-κB pathway activation through RPS3. Cell Death Dis. 2019;10(12). doi:10.1038/s41419-019-2177-x
   Web of Science ®Google Scholar
• Gan X, Chen B, Shen Z, et al. High GPX1 expression promotes esophageal squamous cell carcinoma invasion, migration, proliferation and cisplatin-resistance but can be reduced by vitamin D. Int J Clin Exp Med. 2014.
   Google Scholar
• Miao T, Wang J, Zeng Y, Liu G, Chen X. Polysaccharide-based controlled release systems for therapeutics delivery and tissue engineering: from bench to bedside. Adv Sci. 2018. doi:10.1002/advs.201700513
   Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;1(1):10–29. doi:10.1002/btm2.10003
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986.
   Web of Science ®Google Scholar
• Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55(17):3752–3756.
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998;95(8):4607–4612. doi:10.1073/pnas.95.8.4607
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760. doi:10.1038/nnano.2007.387
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–160. doi:10.1038/nrd1632
   PubMed Web of Science ®Google Scholar
• Domínguez-Ríos R, Sánchez-Ramírez DR, Ruiz-Saray K, et al. Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. Colloids Surfaces B Biointerfaces. 2019. doi:10.1016/j.colsurfb.2019.03.011
   Web of Science ®Google Scholar
• Boulikas T. Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs. 2009;18(8):1197–1218. doi:10.1517/13543780903114168
   PubMed Web of Science ®Google Scholar
• Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res. 2005;25(4):3031–3039.
   PubMed Web of Science ®Google Scholar
• Devarajan P, Tarabishi R, Mishra J, et al. Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res. 2004;24(4):2193–2200.
   PubMed Web of Science ®Google Scholar
• Fedier A, Poyet C, Perucchini D, Boulikas T, Fink D. MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal. Anticancer Drugs. 2006;17(3):315–323. doi:10.1097/00001813-200603000-00010
   Web of Science ®Google Scholar
• Lan X, She J, Lin DA, et al. Microneedle-mediated delivery of lipid-coated cisplatin nanoparticles for efficient and safe cancer therapy. ACS Appl Mater Interfaces. 2018. doi:10.1021/acsami.8b12926
   Web of Science ®Google Scholar
• Guo S, Wang Y, Miao L, et al. Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano. 2013;7(11):9896–9904. doi:10.1021/nn403606m
   Web of Science ®Google Scholar
• Kolishetti N, Dhar S, Valencia PM, et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A. 2010;107(42):17939–17944. doi:10.1073/pnas.1011368107
   PubMed Web of Science ®Google Scholar
• Wang Y, Qian J, Yang M, et al. Doxorubicin/cisplatin co-loaded hyaluronic acid/chitosan-based nanoparticles for in vitro synergistic combination chemotherapy of breast cancer. Carbohydr Polym. 2019;225:115206. doi:10.1016/j.carbpol.2019.115206
   Web of Science ®Google Scholar
• Lee SM, O’Halloran TV, Nguyen ST. Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy. J Am Chem Soc. 2010. doi:10.1021/ja107333g
   Web of Science ®Google Scholar
• Wu H, Jin H, Wang C, et al. Synergistic cisplatin/doxorubicin combination chemotherapy for multidrug-resistant cancer via polymeric nanogels targeting delivery. ACS Appl Mater Interfaces. 2017. doi:10.1021/acsami.6b16844
   Web of Science ®Google Scholar
• Guo XL, Kang XX, Wang YQ, et al. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy. Acta Biomater. 2019. doi:10.1016/j.actbio.2018.12.007
   Web of Science ®Google Scholar
• Zhou D, Cong Y, Qi Y, et al. Overcoming tumor resistance to cisplatin through micelle-mediated combination chemotherapy. Biomater Sci. 2015;3(1):182–191. doi:10.1039/c4bm00305e
   Web of Science ®Google Scholar
• Vivero-Escoto JL, Elnagheeb M. Mesoporous silica nanoparticles loaded with cisplatin and phthalocyanine for combination chemotherapy and photodynamic therapy in vitro. Nanomaterials. 2015;5(4):2302–2316. doi:10.3390/nano5042302
   Web of Science ®Google Scholar
• Shanmugam V, Chien YH, Cheng YS, et al. Oligonucleotides-assembled au nanorod-assisted cancer photothermal ablation and combination chemotherapy with targeted dual-drug delivery of doxorubicin and cisplatin prodrug. ACS Appl Mater Interfaces. 2014;6(6):4382–4393. doi:10.1021/am5000905
   Web of Science ®Google Scholar
• Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM, Miller D. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987;60(12):2869–2872. doi:10.1002/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y
   Web of Science ®Google Scholar
• Sohn JW, Lee SY, Lee SJ, et al. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol. 2006;36(3):137–141. doi:10.1093/jjco/hyi231
   Web of Science ®Google Scholar
• Segawa Y, Kiura K, Takigawa N, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 2010. doi:10.1200/JCO.2009.24.7577
   Web of Science ®Google Scholar
• Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, Van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: a Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1996;14(3):814–820. doi:10.1200/JCO.1996.14.3.814
   PubMed Web of Science ®Google Scholar
• Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a gynecologic oncology group study. J Clin Oncol. 2007. doi:10.1200/JCO.2006.09.4532
   Web of Science ®Google Scholar
• Sato Y, Takayama T, Sagawa T, et al. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol. 2010;66(4):721–728. doi:10.1007/s00280-009-1215-2
   PubMed Web of Science ®Google Scholar
• Duan J, Yang Z, Liu D, Zhang Z, Shi Y. Clinical efficacy of bevacizumab combined with gemcitabine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer. J BUON. 2018;23(5):1402–1406.
   Web of Science ®Google Scholar
• Niho S, Kenmotsu H, Sekine I, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol. 2013;8(7):980–984. doi:10.1097/JTO.0b013e31828f6989
   PubMed Web of Science ®Google Scholar
• Kim M, Keam B, Kim TM, et al. Phase II study of irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancer. Cancer Res Treat. 2017. doi:10.4143/crt.2016.121
   Web of Science ®Google Scholar
• Boku N, Ohtsu A, Shimada Y, et al. Phase ii study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol. 1999;17(1):319. doi:10.1200/jco.1999.17.1.319
   PubMed Web of Science ®Google Scholar
• Dexeus FH, Logothetis CJ, Sella A, et al. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol. 1991;146(5):1284–1287. doi:10.1016/S0022-5347(17)38069-2
   Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999;17(3):968. doi:10.1200/jco.1999.17.3.968
   PubMed Web of Science ®Google Scholar
• Fujita A, Fukuoka S, Takabatake H, Tagaki S, Sekine K. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology. 2000. doi:10.1159/000012185
   Web of Science ®Google Scholar
• Cartei G, Cartei F, Cantone A, et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst. 1993;85(10):794–800. doi:10.1093/jnci/85.10.794
   Google Scholar
• Yun J, Lee J, Park SH, et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer. 2010;46(5):885–891. doi:10.1016/j.ejca.2009.12.015
   PubMed Web of Science ®Google Scholar
• Kang H, Kim TJ, Kim WY, et al. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol. 2008;111(1):106–110. doi:10.1016/j.ygyno.2008.05.033
   PubMed Web of Science ®Google Scholar
• Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol. 2014;20(1):235–241. doi:10.3748/wjg.v20.i1.235
   Web of Science ®Google Scholar
• Peters WA, Rivkin SE, Smith MR, Tesh DE. Cisplatin and Adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors. Gynecol Oncol. 1989. doi:10.1016/0090-8258(89)90166-2
   Web of Science ®Google Scholar
• Ohnuma H, Sato Y, Hirakawa M, et al. Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study. Cancer Chemother Pharmacol. 2018;81(3):539–548. doi:10.1007/s00280-018-3523-x
   Web of Science ®Google Scholar
• Liu L, Peng Z, Huang H, Xu Z, Wei X. Luteolin and apigenin activate the Oct-4/Sox2 signal via NFATc1 in human periodontal ligament cells. Cell Biol Int. 2016;40(10):1094–1106. doi:10.1002/cbin.10648
   Web of Science ®Google Scholar
• Xia C, Bai X, Hou X, et al. Cryptotanshinone reverses cisplatin resistance of human lung carcinoma A549 cells through down-regulating Nrf2 pathway. Cell Physiol Biochem. 2015;37(2):816–824. doi:10.1159/000430398
   PubMedGoogle Scholar
• Sharma R, Gatchie L, Williams IS, et al. Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme. Bioorg Med Chem Lett. 2017;27(24):5400–5403. doi:10.1016/j.bmcl.2017.11.013
   PubMed Web of Science ®Google Scholar
• Donnelly A, Blagg B. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem. 2008;15(26):2702–2717. doi:10.2174/092986708786242895
   PubMed Web of Science ®Google Scholar
• Arafa ESA, Zhu Q, Barakat BM, et al. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res. 2009;69(23):8910–8917. doi:10.1158/0008-5472.CAN-09-1543
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang F, Wu XR. Inhibition of pyruvate kinase M2 markedly reduces chemoresistance of advanced bladder cancer to cisplatin. Sci Rep. 2017. doi:10.1038/srep45983
   Web of Science ®Google Scholar
• Jiang XY, Zhu XS, Xu HY, et al. Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/JNK and potentiates cisplatin efficacy in gastric cancer treatment. Acta Pharmacol Sin. 2017;38(7):1048–1058. doi:10.1038/aps.2016.176
   Web of Science ®Google Scholar
• Chen P, Li J, Jiang HG, Lan T, Chen YC. Curcumin reverses cisplatin resistance in cisplatin-resistant lung cancer cells by inhibiting FA/BRCA pathway. Tumor Biol. 2015. doi:10.1007/s13277-014-2996-4
   Google Scholar
• Leekha A, Gurjar BS, Tyagi A, Rizvi MA, Verma AK. Vitamin C in synergism with cisplatin induces cell death in cervical cancer cells through altered redox cycling and p53 upregulation. J Cancer Res Clin Oncol. 2016;142(12):2503–2514. doi:10.1007/s00432-016-2235-z
   PubMed Web of Science ®Google Scholar
• Hsieh MJ, Wang CW, Lin JT, et al. Celastrol, a plant-derived triterpene, induces cisplatin-resistance nasopharyngeal carcinoma cancer cell apoptosis through ERK1/2 and p38 MAPK signaling pathway. Phytomedicine. 2019;58:152805. doi:10.1016/j.phymed.2018.12.028
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen S, Wei C, et al. Dietary compound proanthocyanidins from Chinese bayberry (Myrica rubra Sieb. et Zucc.) leaves inhibit angiogenesis and regulate cell cycle of cisplatin-resistant ovarian cancer cells via targeting Akt pathway. J Funct Foods. 2018. doi:10.1016/j.jff.2017.11.045
   Web of Science ®Google Scholar
• Sherif IO, Al-Gayyar MMH. Oleuropein potentiates anti-tumor activity of cisplatin against HepG2 through affecting proNGF/NGF balance. Life Sci. 2018;198:87–93. doi:10.1016/j.lfs.2018.02.027
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhu Y, Li S, et al. Terrein performs antitumor functions on esophageal cancer cells by inhibiting cell proliferation and synergistic interaction with cisplatin. Oncol Lett. 2017. doi:10.3892/ol.2017.5758
   Web of Science ®Google Scholar
• Peng XH, Wang Y, Huang D, et al. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin- cisplatin nanoparticles. ACS Nano. 2011;5(12):9480–9493. doi:10.1021/nn202410f
   PubMed Web of Science ®Google Scholar
• Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm. 2007;67(1):1–8. doi:10.1016/j.ejpb.2006.12.017
   Web of Science ®Google Scholar
• Yang T, Zhao P, Rong Z, et al. Anti-tumor efficiency of lipid-coated cisplatin nanoparticles co-loaded with microRNA-375. Theranostics. 2016;6(1):142–154. doi:10.7150/thno.13130
   Web of Science ®Google Scholar
• Zhang J, Miao L, Guo S, et al. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J Control Release. 2014;182:90–96. doi:10.1016/j.jconrel.2014.03.016
   PubMed Web of Science ®Google Scholar
• Kates M, Date A, Yoshida T, et al. Preclinical evaluation of intravesical cisplatin nanoparticles for non–muscle-invasive bladder cancer. Clin Cancer Res. 2017;23(21):6592–6601. doi:10.1158/1078-0432.CCR-17-1082
   Web of Science ®Google Scholar
• Hwang PA, Lin XZ, Kuo KL, Hsu FY. Fabrication and cytotoxicity of fucoidan-cisplatin nanoparticles for macrophage and tumor cells. Materials (Basel). 2017;10(3):291. doi:10.3390/ma10030291
   Web of Science ®Google Scholar
• Xu Y, Han X, Li Y, et al. Sulforaphane mediates glutathione depletion via polymeric nanoparticles to restore cisplatin chemosensitivity. ACS Nano. 2019;13(11):13445–13455. doi:10.1021/acsnano.9b07032
   Web of Science ®Google Scholar
• Chiani M, Milani AT, Nemati M, et al. Anticancer effect of cisplatin-loaded poly (Butylcyanoacrylate) nanoparticles on A172 brain cancer cells line. Asian Pac J Cancer Prev. 2019. doi:10.31557/APJCP.2019.20.1.303
   Google Scholar
• Yu M, Zhang C, Tang Z, Tang X, Xu H. Intratumoral injection of gels containing losartan microspheres and (PLG-g-mPEG)-cisplatin nanoparticles improves drug penetration, retention and anti-tumor activity. Cancer Lett. 2019. doi:10.1016/j.canlet.2018.11.011
   Web of Science ®Google Scholar
• Ghaferi M, Amari S, Mohrir BV, Raza A, Shahmabadi HE, Alavi SE. Preparation, characterization, and evaluation of cisplatin-loaded polybutylcyanoacrylate nanoparticles with improved in vitro and in vivo anticancer activities. Pharmaceuticals. 2020;13(3):44. doi:10.3390/ph13030044
   Web of Science ®Google Scholar
• Khan MM, Madni A, Torchilin V, et al. Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin. Drug Deliv. 2019;26(1):765–772. doi:10.1080/10717544.2019.1642420
   PubMed Web of Science ®Google Scholar
• Mirrahimi M, Abed Z, Beik J, et al. A thermo-responsive alginate nanogel platform co-loaded with gold nanoparticles and cisplatin for combined cancer chemo-photothermal therapy. Pharmacol Res. 2019;143:178–185. doi:10.1016/j.phrs.2019.01.005
   PubMed Web of Science ®Google Scholar
• Zhang C, Nance EA, Mastorakos P, et al. Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats. J Control Release. 2017. doi:10.1016/j.jconrel.2017.03.007
   Web of Science ®Google Scholar
• Ling X, Chen X, Riddell IA, et al. Glutathione-Scavenging Poly(disulfide amide) nanoparticles for the effective delivery of Pt(IV) prodrugs and reversal of cisplatin resistance. Nano Lett. 2018;18(7):4618–4625. doi:10.1021/acs.nanolett.8b01924
   PubMed Web of Science ®Google Scholar
• Aldawsari HM, Singh S. Rapid microwave-assisted cisplatin-loaded solid lipid nanoparticles: synthesis, characterization and anticancer study. Nanomaterials. 2020;10(3):510. doi:10.3390/nano10030510
   Web of Science ®Google Scholar
• Mirrahimi M, Khateri M, Beik J, et al. Enhancement of chemoradiation by co-incorporation of gold nanoparticles and cisplatin into alginate hydrogel. J Biomed Mater Res Part B Appl Biomater. 2019;107(8):2658–2663. doi:10.1002/jbm.b.34356
   Web of Science ®Google Scholar
• Zhang Y, Fu X, Jia J, et al. Glioblastoma therapy using codelivery of cisplatin and glutathione peroxidase targeting siRNA from iron oxide nanoparticles. ACS Appl Mater Interfaces. 2020. doi:10.1021/acsami.0c12042
   Web of Science ®Google Scholar
• Ma X, Khan MW, Zhao P, et al. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity. Int J Nanomedicine. 2019. doi:10.2147/IJN.S196651
   Web of Science ®Google Scholar
• Davidi ES, Dreifuss T, Motiei M, et al. Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer. Head Neck. 2018. doi:10.1002/hed.24935
   Web of Science ®Google Scholar
• Toro-Cordova A, Flores-Cruz M, Santoyo-Salazar J, et al. Liposomes loaded with cisplatin and magnetic nanoparticles: physicochemical characterization, pharmacokinetics, and in-vitro efficacy. Molecules. 2018;23(9):2272. doi:10.3390/molecules23092272
   PubMed Web of Science ®Google Scholar
• Vandghanooni S, Eskandani M, Barar J, Omidi Y. AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells. Nanomedicine. 2018;13(21):2729–2758. doi:10.2217/nnm-2018-0205
   PubMed Web of Science ®Google Scholar
• Nan Y. Lung carcinoma therapy using epidermal growth factor receptor-targeted lipid polymeric nanoparticles co-loaded with cisplatin and doxorubicin. Oncol Rep. 2019. doi:10.3892/or.2019.7323
   Web of Science ®Google Scholar